董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Joseph Edelman | 男 | Director | 65 | 未披露 | 未持股 | 2020-09-04 |
| Leen Kawas | 女 | President, Chief Executive Officer and Director | 35 | 28.70万美元 | 未持股 | 2020-09-04 |
| John M. Fluke, Jr. | 男 | Director | 77 | 未披露 | 未持股 | 2020-09-04 |
| Tadataka Yamada | 男 | Chairman of the Board | 75 | 2.21万美元 | 未持股 | 2020-09-04 |
| James A. Johnson | 男 | Director | 64 | 未披露 | 未持股 | 2020-09-04 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Leen Kawas | 女 | President, Chief Executive Officer and Director | 35 | 28.70万美元 | 未持股 | 2020-09-04 |
| Glenna Mileson | 女 | Chief Financial Officer and Corporate Secretary | 62 | 未披露 | 未持股 | 2020-09-04 |
| Mark Litton | 男 | Chief Operating Officer | 52 | 19.25万美元 | 未持股 | 2020-09-04 |
| Hans Moebius | 男 | Chief Medical Officer | 64 | 未披露 | 未持股 | 2020-09-04 |
| Kevin Church | 男 | Vice President of Discovery | 36 | 13.53万美元 | 未持股 | 2020-09-04 |
董事简历
中英对照 | 中文 | 英文- Joseph Edelman
-
Joseph Edelman担任我们的董事会主席。Edelman先生是Perceptive Advisors的创始人，首席执行官和投资组合经理。自2020年7月起，他还担任Arya Sciences Acquisition Corp Iii（Nasdaq:ARYA）的董事会主席。创立Perceptive Advisors之前，Edelman从1994年到1998年担任Aries Fund（Paramount Capital Asset Management生物技术对冲基金）高级分析师。担任该职位之前，Edelman从1990年到1994年担任Prudential Securities高级生物技术分析师。Edelman先生的职业生涯始于证券行业的梦百合部门，1987年至1990年在Labe，Simpson担任生物技术分析师。Edelman先生在纽约大学（New York University）获得工商管理硕士学位，并在加利福尼亚大学圣地亚哥分校（University of California San Diego）以优异成绩获得心理学学士学位。
Joseph Edelman serves as the Chairman of our board of directors. Mr. Edelman is Founder, Chief Executive Officer and Portfolio Manager of Perceptive Advisors. He has also served as Chairman of the board of directors of ARYA Sciences Acquisition Corp IV Nasdaq: ARYD since January 2021 and served as the Chairman of ARYA Sciences Acquisition Corp. from October 2018 to June 2020 ARYA Sciences Acquisition Corp II from July 2020 to October 2020 and ARYA Sciences Acquisition Corp III from August 2020 to June 2021. Prior to founding Perceptive Advisors, Mr. Edelman was a Senior Analyst at Aries Fund, a Paramount Capital Asset Management biotechnology hedge fund, from 1994 through 1998. Prior to that position, Mr. Edelman was a Senior Biotechnology Analyst at Prudential Securities from 1990 to 1994. Mr. Edelman started his career in the healthcare sector of the securities industry as a Biotechnology Analyst at Labe, Simpson from 1987 to 1990. Mr. Edelman earned an MBA from New York University and a BA, magna cum laude, in psychology from the University of California San Diego. - Joseph Edelman担任我们的董事会主席。Edelman先生是Perceptive Advisors的创始人，首席执行官和投资组合经理。自2020年7月起，他还担任Arya Sciences Acquisition Corp Iii（Nasdaq:ARYA）的董事会主席。创立Perceptive Advisors之前，Edelman从1994年到1998年担任Aries Fund（Paramount Capital Asset Management生物技术对冲基金）高级分析师。担任该职位之前，Edelman从1990年到1994年担任Prudential Securities高级生物技术分析师。Edelman先生的职业生涯始于证券行业的梦百合部门，1987年至1990年在Labe，Simpson担任生物技术分析师。Edelman先生在纽约大学（New York University）获得工商管理硕士学位，并在加利福尼亚大学圣地亚哥分校（University of California San Diego）以优异成绩获得心理学学士学位。
- Joseph Edelman serves as the Chairman of our board of directors. Mr. Edelman is Founder, Chief Executive Officer and Portfolio Manager of Perceptive Advisors. He has also served as Chairman of the board of directors of ARYA Sciences Acquisition Corp IV Nasdaq: ARYD since January 2021 and served as the Chairman of ARYA Sciences Acquisition Corp. from October 2018 to June 2020 ARYA Sciences Acquisition Corp II from July 2020 to October 2020 and ARYA Sciences Acquisition Corp III from August 2020 to June 2021. Prior to founding Perceptive Advisors, Mr. Edelman was a Senior Analyst at Aries Fund, a Paramount Capital Asset Management biotechnology hedge fund, from 1994 through 1998. Prior to that position, Mr. Edelman was a Senior Biotechnology Analyst at Prudential Securities from 1990 to 1994. Mr. Edelman started his career in the healthcare sector of the securities industry as a Biotechnology Analyst at Labe, Simpson from 1987 to 1990. Mr. Edelman earned an MBA from New York University and a BA, magna cum laude, in psychology from the University of California San Diego.
- Leen Kawas
-
Leen Kawas，2014年1月起，担任本公司的首席执行官、董事。此前，Kawas博士曾担任我们的Vice President。Kawas博士在多个董事会任职，包括华盛顿州州长生命科学咨询委员会，阿尔茨海默症药物发现基金会科学审查委员会和阿尔茨海默症协会华盛顿分会委员会。她也曾担任the International Alzheimer’s Association Business Consortium的联席主席。Kawas博士于2011年在华盛顿州立大学（Washington State University）获得分子药理学博士学位，并于2008年在约旦大学（University of Jordan）获得药学学位。
Leen Kawas has served as our chief executive officer and as a member of our board of directors since January 2014. Previously, Dr. Kawas served as our vice president. Dr. Kawas serves on multiple boards, including the Washington Governor’s Life Science Advisory Board, Scientific Review Board for the Alzheimer’s Drug Discovery Foundation, and Alzheimer’s Association - Washington Chapter Board. She also served as the co-chair of the International Alzheimer's Association Business Consortium. Dr. Kawas earned a Ph.D. in molecular pharmacology from Washington State University in 2011 and a pharmacy degree from the University of Jordan in 2008. - Leen Kawas，2014年1月起，担任本公司的首席执行官、董事。此前，Kawas博士曾担任我们的Vice President。Kawas博士在多个董事会任职，包括华盛顿州州长生命科学咨询委员会，阿尔茨海默症药物发现基金会科学审查委员会和阿尔茨海默症协会华盛顿分会委员会。她也曾担任the International Alzheimer’s Association Business Consortium的联席主席。Kawas博士于2011年在华盛顿州立大学（Washington State University）获得分子药理学博士学位，并于2008年在约旦大学（University of Jordan）获得药学学位。
- Leen Kawas has served as our chief executive officer and as a member of our board of directors since January 2014. Previously, Dr. Kawas served as our vice president. Dr. Kawas serves on multiple boards, including the Washington Governor’s Life Science Advisory Board, Scientific Review Board for the Alzheimer’s Drug Discovery Foundation, and Alzheimer’s Association - Washington Chapter Board. She also served as the co-chair of the International Alzheimer's Association Business Consortium. Dr. Kawas earned a Ph.D. in molecular pharmacology from Washington State University in 2011 and a pharmacy degree from the University of Jordan in 2008.
- John M. Fluke, Jr.
-
John M. Fluke, Jr.，是福禄克资本管理有限公司的董事长，一家私人投资公司，并曾担任该职位自1990年以来，他也是临时首席行政人员和CellCyte遗传学公司，生物技术公司的董事，并自2013自2008年起担任该职位。自2011年起担任Pregenen公司是一家生物技术公司，董事长自2011年和Greyrock能源公司自2006年以来超临界技术公司董事兼MicroPlanet技术公司。他此前担任塔利的咖啡公司2005-2011的董事。自1984年起担任公司董事。
John M. Fluke, Jr. has served on our board of directors since December 2014. Mr. Fluke is chairman of Fluke Capital Management, L.P., which he founded in 1976 and was chairman and chief executive officer of the John Fluke Manufacturing Co. until 1990. Mr. Fluke previously served on the boards of PACCAR Inc., CellCyte Genetics Corporation, Cell Therapeutics, Primus International, and American Seafoods Group. Mr. Fluke is a current trustee of the Greater Seattle Chamber of Commerce formerly serving as its chairman and previously served as chairman of the Washington State China Relations Council and a trustee emeritus of the Museum of Flight. He also previously served as chairman of the Washington Technology Center at the University of Washington, which is an organization responsible for managing technology transfers from public universities in Washington state to the private sector for commercialization. Mr. Fluke has also served as chairman of the trustees of Junior Achievement of Washington and president of the Seattle Council of Boy Scouts of America. Mr. Fluke earned an M.S. in electrical engineering from Stanford University in 1966 and a B.S. in electrical engineering from the University of Washington in 1964. - John M. Fluke, Jr.，是福禄克资本管理有限公司的董事长，一家私人投资公司，并曾担任该职位自1990年以来，他也是临时首席行政人员和CellCyte遗传学公司，生物技术公司的董事，并自2013自2008年起担任该职位。自2011年起担任Pregenen公司是一家生物技术公司，董事长自2011年和Greyrock能源公司自2006年以来超临界技术公司董事兼MicroPlanet技术公司。他此前担任塔利的咖啡公司2005-2011的董事。自1984年起担任公司董事。
- John M. Fluke, Jr. has served on our board of directors since December 2014. Mr. Fluke is chairman of Fluke Capital Management, L.P., which he founded in 1976 and was chairman and chief executive officer of the John Fluke Manufacturing Co. until 1990. Mr. Fluke previously served on the boards of PACCAR Inc., CellCyte Genetics Corporation, Cell Therapeutics, Primus International, and American Seafoods Group. Mr. Fluke is a current trustee of the Greater Seattle Chamber of Commerce formerly serving as its chairman and previously served as chairman of the Washington State China Relations Council and a trustee emeritus of the Museum of Flight. He also previously served as chairman of the Washington Technology Center at the University of Washington, which is an organization responsible for managing technology transfers from public universities in Washington state to the private sector for commercialization. Mr. Fluke has also served as chairman of the trustees of Junior Achievement of Washington and president of the Seattle Council of Boy Scouts of America. Mr. Fluke earned an M.S. in electrical engineering from Stanford University in 1966 and a B.S. in electrical engineering from the University of Washington in 1964.
- Tadataka Yamada
-
Tadataka Yamada自2019年8月起担任Icosavax, Inc.的董事会主席。他曾担任Frazier的风险合伙人(2015年6月以来)。从2011年6月到2015年6月，Yamada博士担任Takeda的首席医疗和科学官和董事会成员。从2011年到2021年3月，他担任安捷伦技术公司(一家在纽约证券交易所上市的全球科学仪器制造和临床诊断公司)的董事会成员。山田博士从2016年6月到2019年10月担任董事会的CSL有限,生物技术公司在澳大利亚证券交易所上市,2017年6月以来,他一直担任董事会主席的生物,一个公共基因药物公司。自2019年3月以来，他担任Phathom Pharmaceuticals, Inc.(一家上市生物制药公司)的董事会主席。自2019年6月起，他担任Athira Pharma(一家公开的神经疾病公司)的董事会成员，并自2020年1月起担任Athira的主席。自2018年6月以来，他担任Prometheus Biosciences, Inc.(一家上市生物技术公司)的董事会主席。从2006年6月到2011年6月，Yamada博士曾担任比尔和梅林达·盖茨基金会的全球卫生方案总裁。从2000年到2006年，他担任葛兰素史克公司(GlaxoSmithKline Inc.)的研发主席和董事会成员。在此之前，他在SmithKline Beecham担任研发职位。在加入SmithKline Beecham之前，Yamada博士是密歇根大学医学院(University of Michigan Medical School)内科系主任和密歇根大学医学中心(University of Michigan Medical Center)首席医师。Yamada博士担任the Clinton Health Access Initiative的董事会主席和the National Academy of Medicine的成员。他也是一位皇家医学院,美国医师学会的大师,一位皇家医师学院的职员,美国艺术与科学学会会员和美国胃肠病协会前任主席和美国医师协会。他持有New York University School of Medicine的医学博士学位，以及Stanford University的历史学学士学位。
Tadataka Yamada has served as the Chairman of our board of directors since August 2019. Dr. Yamada has served as a Venture Partner at Frazier since June 2015. From June 2011 to June 2015 Dr. Yamada served as the Chief Medical and Scientific Officer and as a member of the board of directors of Takeda. From 2011 to March 2021 Dr. Yamada served as a member of the board of directors of Agilent Technologies, a global scientific instrument manufacturing and clinical diagnostics company listed on the New York Stock Exchange. From June 2016 to October 2019 Dr. Yamada served on the board of directors of CSL Limited, a biotechnology company that is publicly traded on the Australian Securities Exchange, and since June 2017 he has served as Chairman of the board of directors of Passage Bio, a public genetic medicines company. Since March 2019 Dr. Yamada has served as Chairman of the board of directors of Phathom Pharmaceuticals, Inc., a public biopharmaceutical company. Since June 2019 he has served as a member of the board of directors of Athira Pharma, a public neurologic disease company, and he has served as Athira's chair since January 2020. Since June 2018 Dr. Yamada has served as Chairman of the board of directors of Prometheus Biosciences, Inc., a public biotechnology company. Dr. Yamada previously served as President of the Global Health Program of the Bill & Melinda Gates Foundation from June 2006 to June 2011. From 2000 to 2006 Dr. Yamada was Chairman of Research and Development and a member of the board of directors of GlaxoSmithKline Inc. and prior to that, he held research and development positions at SmithKline Beecham. Prior to joining SmithKline Beecham, Dr. Yamada was Chairman of the Department of Internal Medicine at the University of Michigan Medical School and Physician-in-Chief of the University of Michigan Medical Center. Dr. Yamada serves as chair of the board of directors at the Clinton Health Access Initiative and a member of the National Academy of Medicine. He is also a Fellow of the Imperial College of Medicine, a Master of the American College of Physicians, a Fellow of the Royal College of Physicians, a Member of the American Academy of Arts and Sciences and a past-President of the American Gastroenterological Association and the Association of American Physicians. Dr. Yamada received his M.D. from New York University School of Medicine and a B.A. in history from Stanford University. - Tadataka Yamada自2019年8月起担任Icosavax, Inc.的董事会主席。他曾担任Frazier的风险合伙人(2015年6月以来)。从2011年6月到2015年6月，Yamada博士担任Takeda的首席医疗和科学官和董事会成员。从2011年到2021年3月，他担任安捷伦技术公司(一家在纽约证券交易所上市的全球科学仪器制造和临床诊断公司)的董事会成员。山田博士从2016年6月到2019年10月担任董事会的CSL有限,生物技术公司在澳大利亚证券交易所上市,2017年6月以来,他一直担任董事会主席的生物,一个公共基因药物公司。自2019年3月以来，他担任Phathom Pharmaceuticals, Inc.(一家上市生物制药公司)的董事会主席。自2019年6月起，他担任Athira Pharma(一家公开的神经疾病公司)的董事会成员，并自2020年1月起担任Athira的主席。自2018年6月以来，他担任Prometheus Biosciences, Inc.(一家上市生物技术公司)的董事会主席。从2006年6月到2011年6月，Yamada博士曾担任比尔和梅林达·盖茨基金会的全球卫生方案总裁。从2000年到2006年，他担任葛兰素史克公司(GlaxoSmithKline Inc.)的研发主席和董事会成员。在此之前，他在SmithKline Beecham担任研发职位。在加入SmithKline Beecham之前，Yamada博士是密歇根大学医学院(University of Michigan Medical School)内科系主任和密歇根大学医学中心(University of Michigan Medical Center)首席医师。Yamada博士担任the Clinton Health Access Initiative的董事会主席和the National Academy of Medicine的成员。他也是一位皇家医学院,美国医师学会的大师,一位皇家医师学院的职员,美国艺术与科学学会会员和美国胃肠病协会前任主席和美国医师协会。他持有New York University School of Medicine的医学博士学位，以及Stanford University的历史学学士学位。
- Tadataka Yamada has served as the Chairman of our board of directors since August 2019. Dr. Yamada has served as a Venture Partner at Frazier since June 2015. From June 2011 to June 2015 Dr. Yamada served as the Chief Medical and Scientific Officer and as a member of the board of directors of Takeda. From 2011 to March 2021 Dr. Yamada served as a member of the board of directors of Agilent Technologies, a global scientific instrument manufacturing and clinical diagnostics company listed on the New York Stock Exchange. From June 2016 to October 2019 Dr. Yamada served on the board of directors of CSL Limited, a biotechnology company that is publicly traded on the Australian Securities Exchange, and since June 2017 he has served as Chairman of the board of directors of Passage Bio, a public genetic medicines company. Since March 2019 Dr. Yamada has served as Chairman of the board of directors of Phathom Pharmaceuticals, Inc., a public biopharmaceutical company. Since June 2019 he has served as a member of the board of directors of Athira Pharma, a public neurologic disease company, and he has served as Athira's chair since January 2020. Since June 2018 Dr. Yamada has served as Chairman of the board of directors of Prometheus Biosciences, Inc., a public biotechnology company. Dr. Yamada previously served as President of the Global Health Program of the Bill & Melinda Gates Foundation from June 2006 to June 2011. From 2000 to 2006 Dr. Yamada was Chairman of Research and Development and a member of the board of directors of GlaxoSmithKline Inc. and prior to that, he held research and development positions at SmithKline Beecham. Prior to joining SmithKline Beecham, Dr. Yamada was Chairman of the Department of Internal Medicine at the University of Michigan Medical School and Physician-in-Chief of the University of Michigan Medical Center. Dr. Yamada serves as chair of the board of directors at the Clinton Health Access Initiative and a member of the National Academy of Medicine. He is also a Fellow of the Imperial College of Medicine, a Master of the American College of Physicians, a Fellow of the Royal College of Physicians, a Member of the American Academy of Arts and Sciences and a past-President of the American Gastroenterological Association and the Association of American Physicians. Dr. Yamada received his M.D. from New York University School of Medicine and a B.A. in history from Stanford University.
- James A. Johnson
-
James A. Johnson自2012年10月担任首席财务官。在加入我公司前，Johnson先生从2011年5月到2012年9月是Relypsa, Inc.的首席财务官，该公司是一家临床阶段的生物制药公司。从2009年9月到2010年10月Johnson先生担任ZymoGenetics, Inc.的真幸福造船厂、首席财务官、财务主管和秘书长，该公司是一家在2010年10月被Bristol-Myers Squibb收购的生物制药公司。Johnson先生从2007年7月到2009年9月担任ZymoGenetics的执行副总裁、首席财务官和财务主管；从2001年2月到2007年7月担任ZymoGenetics的高级副总裁、首席财务官和财务主管。Johnson先生从1994年到2001年2月担任Targeted Genetics Corporation的首席财务官。财务主管和秘书长，该公司是一家生物技术公司；从1999年1月到2001年2月担任负责金融和管理的高级副总裁；从1994年到1999年1月担任负责金融的副总裁。从1990年到1994年，Johnson先生担任Immunex Corporation（一家生物制药公司）负责金融的副总裁；从1988年到1990年担任该公司负责金融的董事。Johnson先生从华盛顿大学（University of Washington）获得工商管理学学士学位。
James A. Johnson has served on our board of directors since August 2020. Mr. Johnson previously served as the chief financial officer of Nohla Therapeutics, a cell therapy company. Prior to Nohla, Mr. Johnson served for five years as the chief financial officer of NanoString Technologies, a publicly held provider of life science tools for translational research and molecular diagnostics. During his tenure as chief financial officer at NanoString, Mr. Johnson oversaw strategic and corporate finance activities from private stage through the company’s initial public offering and additional rounds of financing, marking the third initial public offering in his career as a chief financial officer. Prior to joining NanoString, Mr. Johnson served as chief financial officer of Relypsa, Inc., a clinical-stage biopharmaceutical company. Prior to Relypsa, Mr. Johnson served for nearly 10 years as chief financial officer of ZymoGenetics, Inc., until the company was acquired by Bristol-Myers Squibb in October 2010. Previously, he served for seven years as chief financial officer of Targeted Genetics Corporation now Armata Pharmaceuticals and as Vice President of Finance at Immunex Corporation during its evolution from product development to commercial operations. Mr. Johnson received a B.A. in business administration from the University of Washington in 1979. - James A. Johnson自2012年10月担任首席财务官。在加入我公司前，Johnson先生从2011年5月到2012年9月是Relypsa, Inc.的首席财务官，该公司是一家临床阶段的生物制药公司。从2009年9月到2010年10月Johnson先生担任ZymoGenetics, Inc.的真幸福造船厂、首席财务官、财务主管和秘书长，该公司是一家在2010年10月被Bristol-Myers Squibb收购的生物制药公司。Johnson先生从2007年7月到2009年9月担任ZymoGenetics的执行副总裁、首席财务官和财务主管；从2001年2月到2007年7月担任ZymoGenetics的高级副总裁、首席财务官和财务主管。Johnson先生从1994年到2001年2月担任Targeted Genetics Corporation的首席财务官。财务主管和秘书长，该公司是一家生物技术公司；从1999年1月到2001年2月担任负责金融和管理的高级副总裁；从1994年到1999年1月担任负责金融的副总裁。从1990年到1994年，Johnson先生担任Immunex Corporation（一家生物制药公司）负责金融的副总裁；从1988年到1990年担任该公司负责金融的董事。Johnson先生从华盛顿大学（University of Washington）获得工商管理学学士学位。
- James A. Johnson has served on our board of directors since August 2020. Mr. Johnson previously served as the chief financial officer of Nohla Therapeutics, a cell therapy company. Prior to Nohla, Mr. Johnson served for five years as the chief financial officer of NanoString Technologies, a publicly held provider of life science tools for translational research and molecular diagnostics. During his tenure as chief financial officer at NanoString, Mr. Johnson oversaw strategic and corporate finance activities from private stage through the company’s initial public offering and additional rounds of financing, marking the third initial public offering in his career as a chief financial officer. Prior to joining NanoString, Mr. Johnson served as chief financial officer of Relypsa, Inc., a clinical-stage biopharmaceutical company. Prior to Relypsa, Mr. Johnson served for nearly 10 years as chief financial officer of ZymoGenetics, Inc., until the company was acquired by Bristol-Myers Squibb in October 2010. Previously, he served for seven years as chief financial officer of Targeted Genetics Corporation now Armata Pharmaceuticals and as Vice President of Finance at Immunex Corporation during its evolution from product development to commercial operations. Mr. Johnson received a B.A. in business administration from the University of Washington in 1979.
高管简历
中英对照 | 中文 | 英文- Leen Kawas
Leen Kawas，2014年1月起，担任本公司的首席执行官、董事。此前，Kawas博士曾担任我们的Vice President。Kawas博士在多个董事会任职，包括华盛顿州州长生命科学咨询委员会，阿尔茨海默症药物发现基金会科学审查委员会和阿尔茨海默症协会华盛顿分会委员会。她也曾担任the International Alzheimer’s Association Business Consortium的联席主席。Kawas博士于2011年在华盛顿州立大学（Washington State University）获得分子药理学博士学位，并于2008年在约旦大学（University of Jordan）获得药学学位。
Leen Kawas has served as our chief executive officer and as a member of our board of directors since January 2014. Previously, Dr. Kawas served as our vice president. Dr. Kawas serves on multiple boards, including the Washington Governor’s Life Science Advisory Board, Scientific Review Board for the Alzheimer’s Drug Discovery Foundation, and Alzheimer’s Association - Washington Chapter Board. She also served as the co-chair of the International Alzheimer's Association Business Consortium. Dr. Kawas earned a Ph.D. in molecular pharmacology from Washington State University in 2011 and a pharmacy degree from the University of Jordan in 2008.- Leen Kawas，2014年1月起，担任本公司的首席执行官、董事。此前，Kawas博士曾担任我们的Vice President。Kawas博士在多个董事会任职，包括华盛顿州州长生命科学咨询委员会，阿尔茨海默症药物发现基金会科学审查委员会和阿尔茨海默症协会华盛顿分会委员会。她也曾担任the International Alzheimer’s Association Business Consortium的联席主席。Kawas博士于2011年在华盛顿州立大学（Washington State University）获得分子药理学博士学位，并于2008年在约旦大学（University of Jordan）获得药学学位。
- Leen Kawas has served as our chief executive officer and as a member of our board of directors since January 2014. Previously, Dr. Kawas served as our vice president. Dr. Kawas serves on multiple boards, including the Washington Governor’s Life Science Advisory Board, Scientific Review Board for the Alzheimer’s Drug Discovery Foundation, and Alzheimer’s Association - Washington Chapter Board. She also served as the co-chair of the International Alzheimer's Association Business Consortium. Dr. Kawas earned a Ph.D. in molecular pharmacology from Washington State University in 2011 and a pharmacy degree from the University of Jordan in 2008.
- Glenna Mileson
Glenna Mileson自2015年10月起担任我们的首席财务官。在担任我们的首席财务官之前，Mileson女士作为B2B CFO Partners LLC的合伙人向我们提供外包的财务管理服务。2008年5月至2020年7月在B2B CFO Partners LLC任职期间，Mileson女士还为各种中型公司提供财务管理服务，包括Precision Genome Engineering，Inc.。Pregenen，一家生物技术公司，开发基因编辑和细胞信号技术，从2012年到2014年。在此之前，Mileson女士曾担任多个会计和财务领导职位，包括2006年至2008年在营销和广告公司POP担任财务Vice President，1997年至2006年在宏盟集团旗下的广告公司DDB Seattle担任首席财务官/财务总监。她的职业生涯始于担任Laventhol&Horwath公司（国家公共会计师事务所）的审计师和信息系统顾问，在那里她获得注册会计师认证。Mileson女士于1980年在华盛顿大学（University of Washington）获得工商管理学士学位。
Glenna Mileson has served as our chief financial officer since October 2015. Before she served as our chief financial officer, Ms. Mileson provided outsourced financial management services to us as a partner at B2B CFO Partners LLC. While at B2B CFO Partners LLC from May 2008 until July 2020 Ms. Mileson also provided financial management services to a variety of mid-size companies, including to Precision Genome Engineering, Inc. Pregenen, a biotech company developing gene editing and cell signaling technologies, from 2012 to 2014. Before that, Ms. Mileson held a variety of accounting and finance leadership positions including vice president of finance at POP, a marketing and advertising company, from 2006 to 2008 and chief financial officer/director of finance at DDB Seattle, an advertising firm owned by Omnicom Group Inc., from 1997 to 2006. Ms. Mileson began her career as an auditor and information systems consultant with Laventhol & Horwath, a national public accounting firm, where she earned certification as a certified public accountant. Ms. Mileson earned a B.A. in business administration from the University of Washington in 1980.- Glenna Mileson自2015年10月起担任我们的首席财务官。在担任我们的首席财务官之前，Mileson女士作为B2B CFO Partners LLC的合伙人向我们提供外包的财务管理服务。2008年5月至2020年7月在B2B CFO Partners LLC任职期间，Mileson女士还为各种中型公司提供财务管理服务，包括Precision Genome Engineering，Inc.。Pregenen，一家生物技术公司，开发基因编辑和细胞信号技术，从2012年到2014年。在此之前，Mileson女士曾担任多个会计和财务领导职位，包括2006年至2008年在营销和广告公司POP担任财务Vice President，1997年至2006年在宏盟集团旗下的广告公司DDB Seattle担任首席财务官/财务总监。她的职业生涯始于担任Laventhol&Horwath公司（国家公共会计师事务所）的审计师和信息系统顾问，在那里她获得注册会计师认证。Mileson女士于1980年在华盛顿大学（University of Washington）获得工商管理学士学位。
- Glenna Mileson has served as our chief financial officer since October 2015. Before she served as our chief financial officer, Ms. Mileson provided outsourced financial management services to us as a partner at B2B CFO Partners LLC. While at B2B CFO Partners LLC from May 2008 until July 2020 Ms. Mileson also provided financial management services to a variety of mid-size companies, including to Precision Genome Engineering, Inc. Pregenen, a biotech company developing gene editing and cell signaling technologies, from 2012 to 2014. Before that, Ms. Mileson held a variety of accounting and finance leadership positions including vice president of finance at POP, a marketing and advertising company, from 2006 to 2008 and chief financial officer/director of finance at DDB Seattle, an advertising firm owned by Omnicom Group Inc., from 1997 to 2006. Ms. Mileson began her career as an auditor and information systems consultant with Laventhol & Horwath, a national public accounting firm, where she earned certification as a certified public accountant. Ms. Mileson earned a B.A. in business administration from the University of Washington in 1980.
- Mark Litton
Mark Litton自2019年7月起担任我们的首席运营官。在加入AthiraPharma，Inc.之前，利顿博士于2018年8月至2019年4月担任上市生物技术公司Alpine ImmuneSciences，Inc.的总裁兼首席运营官。Litton博士曾于2004年至2018年担任上市生物制药公司AlderBiopharmaceuticals，Inc.的首席商务官，财务主管和秘书，该公司由Litton博士于2004年共同创立，于2019年10月被Lundbeck A/S收购。从1999年到2004年，Litton博士担任Celltech Group的业务发展Vice President，在那里他负责许多新发现和治疗计划的安全、商业化和合作。1999年，Litton博士作为ChiroScience Group plc的员工加入Celltech Group，1999年ChiroScience&8217；与Celltech Group合并后被提升为业务发展Vice President。Litton从1997年到1999年担任Ribozyme Pharmaceuticals Inc.（现为Sirna Therapeutics，Inc.）业务开发经理，该公司是一家生物制药公司，也是AlnylamPharmaceuticals，Inc.的全资子公司，他在该公司帮助与礼来公司建立了关系，Roche Bioscience和GlaxoWellcome plc（现为GlaxoSmithKline plc）是一家生物制药公司。Litton从1991年到1994年担任DNAX Research Institute（Schering-Plough（现为Merck&Co.，一家上市制药公司）研究设施）研究助理。Litton博士于1997年在斯德哥尔摩大学（Stockholm University）获得免疫学博士学位，于1994年在圣克拉拉大学（Santa Clara University）获得工商管理硕士学位，并于1990年在加利福尼亚大学圣克鲁斯分校（University of California Santa Cruz）获得生物化学学士学位。
Mark Litton has served as our chief operating officer since July 2019. Prior to joining Athira Pharma, Inc., Dr. Litton served as the president and chief operating officer of Alpine Immune Sciences, Inc., a publicly traded biotechnology company, from August 2018 to April 2019. Dr. Litton served as the chief business officer, treasurer, and secretary from 2004 to 2018 of Alder BioPharmaceuticals, Inc., a publicly traded biopharmaceutical company co-founded by Dr. Litton in 2004 which was acquired by Lundbeck A/S in October 2019. From 1999 to 2004 Dr. Litton served as vice president of business development for Celltech Group, where he was responsible for securing, commercializing, and partnering on numerous novel discoveries and therapeutic programs. In 1999 Dr. Litton joined Celltech Group as an employee of Chiroscience Group plc and was later promoted to vice president of business development after Chiroscience’s merger with Celltech Group in 1999. From 1997 to 1999 Dr. Litton served as the manager of business development for Ribozyme Pharmaceuticals Inc. now Sirna Therapeutics, Inc., a biopharmaceutical company and wholly owned subsidiary of Alnylam Pharmaceuticals, Inc., where he helped form relationships with Eli Lilly and Company, Roche Bioscience and GlaxoWellcome plc (now GlaxoSmithKline plc) a biopharmaceutical company. From 1991 to 1994 Dr. Litton served as a research associate for DNAX Research Institute, a research facility of Schering-Plough (now Merck & Co., a publicly traded pharmaceutical company). Dr. Litton earned a Ph.D. in immunology from Stockholm University in 1997 an M.B.A. from Santa Clara University in 1994 and a B.S. in biochemistry from the University of California Santa Cruz in 1990.- Mark Litton自2019年7月起担任我们的首席运营官。在加入AthiraPharma，Inc.之前，利顿博士于2018年8月至2019年4月担任上市生物技术公司Alpine ImmuneSciences，Inc.的总裁兼首席运营官。Litton博士曾于2004年至2018年担任上市生物制药公司AlderBiopharmaceuticals，Inc.的首席商务官，财务主管和秘书，该公司由Litton博士于2004年共同创立，于2019年10月被Lundbeck A/S收购。从1999年到2004年，Litton博士担任Celltech Group的业务发展Vice President，在那里他负责许多新发现和治疗计划的安全、商业化和合作。1999年，Litton博士作为ChiroScience Group plc的员工加入Celltech Group，1999年ChiroScience&8217；与Celltech Group合并后被提升为业务发展Vice President。Litton从1997年到1999年担任Ribozyme Pharmaceuticals Inc.（现为Sirna Therapeutics，Inc.）业务开发经理，该公司是一家生物制药公司，也是AlnylamPharmaceuticals，Inc.的全资子公司，他在该公司帮助与礼来公司建立了关系，Roche Bioscience和GlaxoWellcome plc（现为GlaxoSmithKline plc）是一家生物制药公司。Litton从1991年到1994年担任DNAX Research Institute（Schering-Plough（现为Merck&Co.，一家上市制药公司）研究设施）研究助理。Litton博士于1997年在斯德哥尔摩大学（Stockholm University）获得免疫学博士学位，于1994年在圣克拉拉大学（Santa Clara University）获得工商管理硕士学位，并于1990年在加利福尼亚大学圣克鲁斯分校（University of California Santa Cruz）获得生物化学学士学位。
- Mark Litton has served as our chief operating officer since July 2019. Prior to joining Athira Pharma, Inc., Dr. Litton served as the president and chief operating officer of Alpine Immune Sciences, Inc., a publicly traded biotechnology company, from August 2018 to April 2019. Dr. Litton served as the chief business officer, treasurer, and secretary from 2004 to 2018 of Alder BioPharmaceuticals, Inc., a publicly traded biopharmaceutical company co-founded by Dr. Litton in 2004 which was acquired by Lundbeck A/S in October 2019. From 1999 to 2004 Dr. Litton served as vice president of business development for Celltech Group, where he was responsible for securing, commercializing, and partnering on numerous novel discoveries and therapeutic programs. In 1999 Dr. Litton joined Celltech Group as an employee of Chiroscience Group plc and was later promoted to vice president of business development after Chiroscience’s merger with Celltech Group in 1999. From 1997 to 1999 Dr. Litton served as the manager of business development for Ribozyme Pharmaceuticals Inc. now Sirna Therapeutics, Inc., a biopharmaceutical company and wholly owned subsidiary of Alnylam Pharmaceuticals, Inc., where he helped form relationships with Eli Lilly and Company, Roche Bioscience and GlaxoWellcome plc (now GlaxoSmithKline plc) a biopharmaceutical company. From 1991 to 1994 Dr. Litton served as a research associate for DNAX Research Institute, a research facility of Schering-Plough (now Merck & Co., a publicly traded pharmaceutical company). Dr. Litton earned a Ph.D. in immunology from Stockholm University in 1997 an M.B.A. from Santa Clara University in 1994 and a B.S. in biochemistry from the University of California Santa Cruz in 1990.
- Hans Moebius
Hans Moebius自2019年4月起担任我们的首席医疗官。在加入AthiraPharma，Inc.之前，Moebius博士共同创立了专注于靶向药物救援的Exciva GmbH公司，并于2016年至2019年担任其首席执行官兼首席医疗官，自2020年4月起再次担任代理首席医疗官。Moebius博士还于2016年10月起担任Rodin Therapeutics的科学顾问委员会成员，直到公司于2019年12月出售给Alkermes为止。在Rodin Therapeutics，他还于2016年12月至2018年4月担任代理首席医疗官。在此之前，Moebius博士曾担任Chase Pharmaceuticals临床研究执行Vice President，直到该公司于2016年被Allergan收购。Moebius博士于1983年在海德堡大学（University of Heidelberg）获得实验药理学博士学位，并于1976年在德国凯泽斯劳滕大学（University of Kaiserslautern）获得化学学士学位。Moebius博士于1982年在海德堡卡尔斯大学（Karls University of Heidelberg）完成医学研究，并于1986年至1991年在法兰克福/美因歌德大学（Goethe University Frankfurt/Main）完成住院治疗后获得神经病学和精神病学委员会认证。1984-1986年在Max-Planck-Institute for Brain Research的研究任期内，他讲授神经病理学和神经科学。Moebius博士还持有EUCOR University Basel/Switzerland，Freiburg/Germany和Strasbourg/France的欧洲制药医学ECPM证书。
Hans Moebius has served as our chief medical officer since April 2019. Prior to joining Athira Pharma, Inc., Dr. Moebius co-founded Exciva GmbH, a company focusing on targeted drug rescue, and served as its chief executive officer and chief medical officer from 2016 to 2019 and again as acting chief medical officer since April 2020. Dr. Moebius also served as scientific advisory board member at Rodin Therapeutics from October 2016 until the company was sold to Alkermes in December 2019. At Rodin Therapeutics, he also served as acting chief medical officer from December 2016 to April 2018. Prior to that, Dr. Moebius served as executive vice president of clinical research at CHASE Pharmaceuticals, until the company was acquired by Allergan in 2016. Dr. Moebius earned his Ph.D. in experimental pharmacology from the University of Heidelberg in 1983 and a B.S. in chemistry from the University of Kaiserslautern, Germany, in 1976. Dr. Moebius completed his medical studies at the Karls University of Heidelberg in 1982 and was board certified in neurology and psychiatry after completion of residencies at the Goethe University Frankfurt/Main from 1986-1991. During his research tenure at the Max-Planck-Institute for Brain Research from 1984-1986 he lectured in neuropathology and neuroscience. Dr. Moebius also holds the European Certificate in Pharmaceutical Medicine ECPM from the EUCOR Universities Basel/Switzerland, Freiburg/Germany and Strasbourg/France.- Hans Moebius自2019年4月起担任我们的首席医疗官。在加入AthiraPharma，Inc.之前，Moebius博士共同创立了专注于靶向药物救援的Exciva GmbH公司，并于2016年至2019年担任其首席执行官兼首席医疗官，自2020年4月起再次担任代理首席医疗官。Moebius博士还于2016年10月起担任Rodin Therapeutics的科学顾问委员会成员，直到公司于2019年12月出售给Alkermes为止。在Rodin Therapeutics，他还于2016年12月至2018年4月担任代理首席医疗官。在此之前，Moebius博士曾担任Chase Pharmaceuticals临床研究执行Vice President，直到该公司于2016年被Allergan收购。Moebius博士于1983年在海德堡大学（University of Heidelberg）获得实验药理学博士学位，并于1976年在德国凯泽斯劳滕大学（University of Kaiserslautern）获得化学学士学位。Moebius博士于1982年在海德堡卡尔斯大学（Karls University of Heidelberg）完成医学研究，并于1986年至1991年在法兰克福/美因歌德大学（Goethe University Frankfurt/Main）完成住院治疗后获得神经病学和精神病学委员会认证。1984-1986年在Max-Planck-Institute for Brain Research的研究任期内，他讲授神经病理学和神经科学。Moebius博士还持有EUCOR University Basel/Switzerland，Freiburg/Germany和Strasbourg/France的欧洲制药医学ECPM证书。
- Hans Moebius has served as our chief medical officer since April 2019. Prior to joining Athira Pharma, Inc., Dr. Moebius co-founded Exciva GmbH, a company focusing on targeted drug rescue, and served as its chief executive officer and chief medical officer from 2016 to 2019 and again as acting chief medical officer since April 2020. Dr. Moebius also served as scientific advisory board member at Rodin Therapeutics from October 2016 until the company was sold to Alkermes in December 2019. At Rodin Therapeutics, he also served as acting chief medical officer from December 2016 to April 2018. Prior to that, Dr. Moebius served as executive vice president of clinical research at CHASE Pharmaceuticals, until the company was acquired by Allergan in 2016. Dr. Moebius earned his Ph.D. in experimental pharmacology from the University of Heidelberg in 1983 and a B.S. in chemistry from the University of Kaiserslautern, Germany, in 1976. Dr. Moebius completed his medical studies at the Karls University of Heidelberg in 1982 and was board certified in neurology and psychiatry after completion of residencies at the Goethe University Frankfurt/Main from 1986-1991. During his research tenure at the Max-Planck-Institute for Brain Research from 1984-1986 he lectured in neuropathology and neuroscience. Dr. Moebius also holds the European Certificate in Pharmaceutical Medicine ECPM from the EUCOR Universities Basel/Switzerland, Freiburg/Germany and Strasbourg/France.
- Kevin Church
凯文·丘奇（Kevin Church）自2016年以来一直在阿提拉担任多个职位，包括研究科学家，探索总监，现为探索Vice President。Church博士于2016年在华盛顿州立大学（Washington State University）获得分子生物学博士学位，在此之前于2006年在爱达荷大学（University of Idaho）获得微生物学学士学位。在研究生院期间，Church博士因其研究生教学助学金的卓越表现而获得认可。Church博士的研究生工作主要专注于开发用于治疗胰腺癌的新型疗法，但也包括与糖尿病溃疡和神经退行性疾病（例如帕金森氏病痴呆和阿尔茨海默病）的治疗有关的研究。
Kevin Church has served in various roles at Athira since 2016 including research scientist, director of discovery, now as vice president of discovery. Dr. Church earned his Ph.D. in molecular biosciences from Washington State University in 2016 and prior to that earned his B.S. in microbiology from the University of Idaho in 2006. While in graduate school, Dr. Church was recognized for excellence in his graduate teaching assistantships. Dr. Church’s graduate work primarily focused on the development of novel therapeutics for the treatment of pancreatic cancer, but also included research relating to the treatment of diabetic ulcers and neurodegenerative diseases such as Parkinson’s disease dementia and Alzheimer’s disease.- 凯文·丘奇（Kevin Church）自2016年以来一直在阿提拉担任多个职位，包括研究科学家，探索总监，现为探索Vice President。Church博士于2016年在华盛顿州立大学（Washington State University）获得分子生物学博士学位，在此之前于2006年在爱达荷大学（University of Idaho）获得微生物学学士学位。在研究生院期间，Church博士因其研究生教学助学金的卓越表现而获得认可。Church博士的研究生工作主要专注于开发用于治疗胰腺癌的新型疗法，但也包括与糖尿病溃疡和神经退行性疾病（例如帕金森氏病痴呆和阿尔茨海默病）的治疗有关的研究。
- Kevin Church has served in various roles at Athira since 2016 including research scientist, director of discovery, now as vice president of discovery. Dr. Church earned his Ph.D. in molecular biosciences from Washington State University in 2016 and prior to that earned his B.S. in microbiology from the University of Idaho in 2006. While in graduate school, Dr. Church was recognized for excellence in his graduate teaching assistantships. Dr. Church’s graduate work primarily focused on the development of novel therapeutics for the treatment of pancreatic cancer, but also included research relating to the treatment of diabetic ulcers and neurodegenerative diseases such as Parkinson’s disease dementia and Alzheimer’s disease.